PHTS is granted an International Classification of Diseases (ICD) Code! - Click here for more information.
Dr Waddell has over 30 years’ experience in the pharmaceutical R&D sector and has worked in a variety of drug discovery settings. He has held various leadership positions at AstraZeneca over a period of almost 20 years. Other key positions held by Ian include head of biology in the Drug Discovery Unit at the Cancer Research UK Manchester Institute, and Chief Scientific Officer of early Discovery at the global Contract Research Organisation Charles River laboratories. Dr Waddell is also currently the Chief Scientific Officer at CUMULUS Oncology, an Edinburgh based cancer focused accelerator suite.
Ian is a biochemist by training with extensive expertise in Oncology focused drug discovery. He gained a BSc and PhD in Biochemistry at the University of Dundee. After 2 post docs he returned to Dundee and spent 5 years as a lecturer in Molecular Medicine in the Department of Child Health at Ninewell’s Hospital and Medical School before joining Zeneca in 1993.